Abstract
Since the global withdrawal of Sabin 2 oral poliovirus vaccine (OPV) from routine immunization, the Global Polio Eradication Initiative (GPEI) has reported multiple circulating vaccine-derived poliovirus type 2 (cVDPV2) outbreaks. cVDPV2 outbreaks are controlled with mass Sabin 2 OPV vaccination campaigns, which carry a small but serious risk of seeding future cVDPV2 outbreaks. Accurate forecasting models are essential for quantifying current and future cVDPV2 outbreak risk following Sabin 2 OPV campaigns, but it is unclear whether household community structure influences vaccine virus transmission or is relevant for assessing cVDPV2 outbreak risk. Here, we developed an agent-based model of Sabin 2 vaccine transmission to assess the role of household community structure on vaccine virus transmission following a mass OPV campaign performed in Matlab, Bangladesh. Household community structure strongly limits vaccine virus transmission to local community members and ignoring it overestimates outbreak risk in terms of emergence probability, duration, and epidemic size.
Competing Interest Statement
Grant funding was obtained from the Bill & Melinda Gates Foundation. ASB, is employed by the funder and contributed to the designing of the original clinical trial, model interpretation and writing of the report. All other authors declare no competing interests. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.
Funding Statement
This study was funded by the Bill & Melinda Gates Foundation (OPP112545 to Petri and Taniuchi, OPP1198444 to Taniuchi).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This original clinical trial (ClinicalTrials.gov, number NCT02477046) was done according to the guidelines of the Declaration of Helsinki. The protocol was approved by the Research Review Committee (RRC) and Ethical Review Committee (ERC) of the icddr,b and the Institutional Review Board of the University of Virginia.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data requests regarding the clinical trial should be made to the Dr. Mami Taniuchi. This trial is registered at ClinicalTrials.gov, number NCT02477046. The model and code used in this study will be available on Github (https://github.com/InstituteforDiseaseModeling/MultiscaleModeling.git) at the time of publication.
